You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 296 No. 22, December 13, 2006 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Commentary
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (6)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Medical Ethics
 •Diagnosis
 •Genetic Disorders
 •Alert me on articles by topic

Preimplantation Genetic Diagnosis for Cancer Syndromes

A New Challenge for Preventive Medicine

Kenneth Offit, MD, MPH; Michal Sagi, PhD; Karen Hurley, PhD

JAMA. 2006;296:2727-2730.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Over the next decade, health care professionals may increasingly be involved in discussions of reproductive options when providing preventive medicine guidance to patients and their families affected by hereditary cancer syndromes. Preimplantation genetic diagnosis (PGD) is one means of assisted reproductive technology (ART) wherein embryos that do not inherit a familial mutation are selected for implantation and gestation. Recently, we documented 55 published reports as well as unpublished experiences using ART for 22 common predisposition syndromes, including hereditary breast, ovarian, and colon cancer.1

Because progress in PGD has occurred only recently, guiding reproductive choice with cancer genetic tests has not been included in professional guidelines.2 Herein we outline some of the regulatory, ethical, and social issues raised by the introduction of PGD into routine care of families affected by hereditary cancer. We offer an analytic framework to address these issues . . . [Full Text of this Article]

Factors Driving Uptake of ART in the Setting of Cancer Syndromes

Author Affiliations: Clinical Genetics Service, Department of Medicine (Dr Offit) and Department of Psychiatry (Dr Hurley), Memorial Sloan-Kettering Cancer Center, New York, NY; and Department of Human Genetics, Hadassah-Hebrew University Hospital, Jerusalem, Israel (Dr Sagi).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Preimplantation genetic diagnosis: a step by step guide to recent Italian ethical and legislative troubles
Turillazzi and Fineschi
J. Med. Ethics 2008;34:e21-e21.
ABSTRACT | FULL TEXT  

Management of an Inherited Predisposition to Breast Cancer
Robson and Offit
NEJM 2007;357:154-162.
FULL TEXT  

The Role of Genetic Testing for Cancer Susceptibility in Gynecologic Practice
Karlan et al.
Obstet Gynecol 2007;110:155-167.
ABSTRACT | FULL TEXT  

In Reply
Offit et al.
JCO 2007;25:913-913.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.